Correspondence 0000059478-23-000264 from ELI LILLY & Co (LLY) (CIK 0000059478) (LLY)
ELI LILLY & Co (LLY) (CIK 0000059478)
Date: Oct. 5, 2023 · CIK: 0000059478 · Accession: 0000059478-23-000264
AI Filing Summary & Sentiment
File numbers found in text: 001-06351
Referenced dates: September 29, 2023
Letter
Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission Attention: Anuja A. Majmudar and Karina Dorin Re: Eli Lilly and Company Form 10-K for the fiscal year ended December 31, 2022 Response dated September 20, 2023 File No. 001-06351
Dear Anuja A. Majmudar and Karina Dorin,
This letter is to confirm our telephone conversation through counsel with you on October 2, 2023 regarding our request for an extension of time to respond to your comment letter dated September 29, 2023. As discussed, we require additional time to prepare a response to your letter. As a result, we respectfully request that you allow us to submit our response by October 29, 2023.
If you have any questions about this response or require additional information, please contact me at (224) 234-2374.
Sincerely yours,
Eli Lilly and Company
Show Raw Text
CORRESP 1 filename1.htm Document October 5, 2023 By EDGAR submission Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Attention: Anuja A. Majmudar and Karina Dorin Re: Eli Lilly and Company Form 10-K for the fiscal year ended December 31, 2022 Response dated September 20, 2023 File No. 001-06351 Dear Anuja A. Majmudar and Karina Dorin, This letter is to confirm our telephone conversation through counsel with you on October 2, 2023 regarding our request for an extension of time to respond to your comment letter dated September 29, 2023. As discussed, we require additional time to prepare a response to your letter. As a result, we respectfully request that you allow us to submit our response by October 29, 2023. If you have any questions about this response or require additional information, please contact me at (224) 234-2374. Sincerely yours, Eli Lilly and Company By: /s/ Christopher Anderson Associate Vice President – Leader of Corporate Securities and Assistant Secretary cc: Donald A. Zakrowski, Senior Vice President, Finance, and Chief Accounting Officer Eli Lilly and Company